Intervacc is trading at SEK 1.05, up 5.02%, amid broader biotech-sector strength.
- No major company-specific announcement was found for September 18, 2026; the latest release only announced an October 1 healthcare-conference presentation.
- Biotech is up 2.55%, supported by improving pharmaceutical demand, R&D investment, funding conditions, and M&A optimism.
- The move therefore appears primarily sector-driven rather than linked to fresh company news.